Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy
| Autor: | Sajitha Sachchithanantham, Ashutosh D. Wechalekar, Kwee Yong, Mark A. Smith, Rakesh Popat, Helen J. Lachmann, Richa Manwani, Sarah Worthington, Raakhee Shah, Julian D. Gillmore, Neil Rabin, Simon Cheesman, Shameem Mahmood, Faye Sharpley, Philip N. Hawkins, Charalampia Kyriakou |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Cardiac function curve
Adult medicine.medical_specialty Antineoplastic Agents Gastroenterology Bortezomib Cohort Studies 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine AL amyloidosis Medicine Humans Immunoglobulin Light-chain Amyloidosis Glucocorticoids Aged business.industry Standard treatment Amyloidosis Contraindications Drug Peripheral Nervous System Diseases Hematology Middle Aged medicine.disease Carfilzomib Peripheral Treatment Outcome chemistry Autonomic Nervous System Diseases 030220 oncology & carcinogenesis Cohort Drug Therapy Combination business Oligopeptides Proteasome Inhibitors 030215 immunology medicine.drug |
| Zdroj: | British journal of haematologyReferences. 187(5) |
| ISSN: | 1365-2141 |
| Popis: | Bortezomib is standard treatment in AL amyloidosis (AL), but is contraindicated in patients with significant neuropathy. Carfilzomib, a second-generation proteosomal inhibitor, results in a lower incidence of neuropathy than bortezomib, but data in AL is scant. We report a cohort of five AL patients treated with upfront carfilzomib. All had cardiac, peripheral and autonomic neuropathy at presentation. All achieved at least a very good partial haematological response. There was no worsening in cardiac function, peripheral or autonomic neuropathy. Carfilzomib is an effective upfront treatment option in AL patients with peripheral and/or autonomic neuropathy (without severe cardiac or renal involvement). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text